Dupilumab, Immune Surveillance And Malignancy: What Does The Literature Reveal?

Dupilumab is an IgG4-monoclonal antibody binding IL-4 receptor alpha, which inhibits downstream IL-4 and IL-13 signaling via JAK-STAT. Modulation of this pathway has been linked to the progression of solid and hematological malignancy. Widely used in sinusitis, asthma and eczema, the influence of dupilumab on oncogenic potential is unclear. The reports of various malignancies developing after dupilumab use are concerning and warrant investigation.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research